Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Terminated 1Suspended 1Recruiting 1

Sponsor Class

OTHER 18INDUSTRY 3NIH 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 3Neuroendocrine Tumors 1Hypoxia 1Colorectal Cancer Metastatic 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × Ethiodized Oil × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

NCT05435014 2026-04-14

T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma

T-ACE Medical Co., Ltd

Phase 1/2 Suspended
82 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01387932 2021-11-30

HiQuality

Merit Medical Systems, Inc.

Phase 3 Terminated
235 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡